nipah
viru
niv
highli
pathogen
reemerg
viru
caus
outbreak
south
east
asia
current
approv
licens
vaccin
antivir
exist
investig
efficaci
niv
b
simian
adenovirusbas
vaccin
encod
niv
glycoprotein
g
bangladesh
syrian
hamster
primeonli
well
primeboost
vaccin
result
uniform
protect
lethal
challeng
niv
bangladesh
anim
surviv
challeng
unabl
find
infecti
viru
either
oral
swab
lung
brain
tissu
furthermor
patholog
lung
damag
observ
singledos
niv
b
also
prevent
diseas
lethal
heterolog
challeng
niv
malaysia
unabl
detect
infecti
viru
swab
tissu
anim
challeng
heterolog
strain
limit
amount
viral
rna
could
found
lung
tissu
situ
hybrid
singl
dose
niv
b
also
provid
partial
protect
hendra
viru
passiv
transfer
antibodi
elicit
niv
b
vaccin
partial
protect
syrian
hamster
niv
bangladesh
data
conclud
niv
b
suitabl
candid
niv
vaccin
preclin
develop
nipah
viru
discov
outbreak
malaysia
sinc
sever
outbreak
report
bangladesh
india
although
outbreak
rel
small
high
casefat
rate
report
furthermor
humantoplo
neglect
tropic
diseas
http
doi
introduct
vaccin
fulfil
requir
make
promis
platform
vector
replicationdefici
simian
adenoviru
vector
use
produc
sever
vaccin
clinic
develop
common
featur
vaccin
low
reactogen
strong
immunogen
absenc
vector
replic
immun
import
safeti
featur
preclin
studi
singl
dose
vector
vaccin
shown
protect
infect
rift
valley
fever
viru
middl
east
respiratori
syndrom
coronaviru
mycobacterium
tuberculosi
zika
viru
larg
scale
manufactur
perform
replicationdefici
adenovir
vector
vaccin
ebola
one
vaccin
licens
anoth
advanc
clinic
develop
simpl
thermostabil
process
allow
vaccin
storag
ambient
temperatur
remov
need
cold
chain
storag
ship
report
preclin
immunogen
efficaci
test
niv
b
anim
experi
approv
receiv
institut
anim
care
use
committe
iacuc
rocki
mountain
laboratori
experi
perform
associ
assess
accredit
laboratori
anim
careapprov
facil
certifi
staff
follow
guidelin
basic
principl
nih
guid
care
use
laboratori
anim
anim
welfar
act
unit
state
depart
agricultur
unit
state
public
health
servic
polici
human
care
use
laboratori
anim
protocol
institut
biosafeti
committe
ibc
approv
work
infecti
niv
hendra
viru
hev
strain
condit
sampl
inactiv
perform
accord
ibcapprov
standard
oper
procedur
remov
specimen
high
contain
henipaviru
isol
obtain
special
pathogen
branch
center
diseas
control
prevent
atlanta
ga
public
health
agenc
winnipeg
canada
niv
bangladesh
genbank
niv
malaysia
genbank
hev
genbank
passag
three
four
three
time
cell
respect
viru
propag
manuscript
perform
cell
dulbecco
modifi
eagl
medium
dmem
sigma
supplement
fetal
bovin
serum
gibco
mm
lglutamin
gibco
uml
penicillin
gibco
streptomycin
gibco
dmem
cell
maintain
dmem
supplement
fetal
bovin
serum
mm
l
glutamin
uml
penicillin
streptomycin
glycoprotein
g
gene
nipah
viru
bangladesh
outbreak
genbank
access
number
codon
optim
human
synthes
geneart
thermo
fisher
scientif
synthes
g
gene
clone
transgen
express
plasmid
compris
modifi
human
cytomegaloviru
immedi
earli
promot
cmv
promot
tetracyclin
oper
teto
site
polyadenyl
signal
bovin
growth
hormon
bgh
result
express
cassett
insert
locu
genom
clone
use
sitespecif
recombin
viru
rescu
propag
cell
invitrogen
purif
cscl
gradient
ultracentrifug
viru
titer
previous
describ
dose
vaccin
base
infecti
unit
iu
femal
golden
syrian
hamster
week
old
purchas
envigo
anim
vaccin
im
iu
vaccin
inject
im
salin
thigh
total
volum
homolog
challeng
vaccin
experi
anim
vaccin
andor
heterolog
challeng
experi
anim
vaccin
three
day
prior
vaccin
viru
challeng
anim
bled
via
orbit
sinu
punctur
anim
challeng
viru
dmem
via
ip
inocul
niv
bangladesh
x
tcid
niv
malaysia
x
tcid
hev
x
tcid
chose
ip
rout
uniformli
lethal
challeng
rout
abl
compar
previous
conduct
vaccin
experi
studi
group
hamster
util
four
anim
euthan
hev
niv
day
post
inocul
remain
six
anim
follow
day
post
challeng
weight
record
daili
day
post
infect
oropharyng
swab
taken
daili
day
post
inocul
ml
dmem
anim
euthan
weight
loss
record
sever
diseas
sign
eg
difficulti
breath
paralysi
observ
upon
euthanasia
blood
tissu
collect
subsequ
analyz
virolog
histolog
approv
iacuc
femal
golden
syrian
hamster
week
old
purchas
envigo
fifteen
anim
vaccin
either
niv
b
gfp
describ
day
serum
collect
serum
collect
via
cardiac
punctur
pool
per
vaccin
group
igg
purifi
use
mabtrap
kit
sigma
accord
manufactur
instruct
ml
serum
purifi
igg
filter
filter
dilut
ml
steril
pb
ten
hamster
immun
via
ip
inject
use
per
hamster
anim
challeng
describ
one
day
post
treatment
studi
group
hamster
util
four
anim
euthan
day
post
challeng
remain
six
anim
follow
day
post
challeng
weight
record
daili
day
post
challeng
oropharyng
swab
taken
daili
day
post
inocul
ml
dmem
anim
euthan
weight
loss
record
sever
diseas
sign
eg
difficulti
breath
paralysi
observ
upon
euthanasia
blood
tissu
collect
subsequ
analyz
virolog
histolog
approv
iacuc
viru
titrat
perform
endpoint
titrat
cell
inocul
tenfold
serial
dilut
viru
swab
media
tissu
homogen
incub
co
tissu
homogen
dilut
remov
wash
twice
pb
replac
dmem
cytopath
effect
score
dpi
tcid
calcul
replic
spearmankarb
method
ad
cell
incub
co
dpi
cytopath
effect
score
viru
neutral
titer
express
reciproc
valu
highest
dilut
serum
still
inhibit
viru
replic
nivg
malaysia
residu
gene
access
number
clone
phlsec
mammalian
express
vector
nivf
malaysia
residu
gene
access
number
clone
phlsec
vector
contain
ctermin
gcnt
trimer
motif
construct
transient
express
human
embryon
kidney
hek
cell
roller
bottl
describ
previous
supernat
harvest
hour
transfect
diafiltr
use
akta
flux
system
ge
healthcar
either
pb
ph
nivg
buffer
contain
mm
tri
mm
nacl
ph
nivf
protein
purifi
ninta
immobil
metalaffin
chromatographi
use
histrap
hp
column
ge
healthcar
follow
size
exclus
chromatographi
nivg
purifi
use
superdex
increas
gl
column
ge
healthcar
equilibr
pb
ph
nivf
purifi
use
superos
increas
gl
column
ge
healthcar
equilibr
mm
tri
mm
nacl
ph
maxisorp
plate
nunc
coat
overnight
g
f
protein
per
plate
carbbicarb
bind
buffer
g
khco
g
na
co
l
distil
water
block
milk
pb
tween
pbst
serum
serial
dilut
start
dilut
milk
pbst
incub
rt
hr
antibodi
detect
use
affinitypurifi
antibodi
peroxidaselabel
goatantihamst
igg
fisher
milk
pbst
tmb
peroxidas
substrat
seracar
read
nm
well
wash
pbst
step
prior
use
f
g
protein
base
niv
malaysia
establish
crossreact
niv
bangladesh
antibodi
suffici
usag
elisa
test
sera
known
posit
niv
bangladesh
antibodi
necropsi
tissu
sampl
perform
accord
ibcapprov
protocol
harvest
tissu
fix
minimum
day
neutralbuff
formalin
subsequ
embed
paraffin
hematoxylin
eosin
h
e
stain
situ
hybrid
ish
perform
tissu
section
cell
block
detect
niv
hev
viral
rna
perform
use
rnascop
ffpe
assay
advanc
cell
diagnost
inc
newark
usa
previous
describ
accord
manufactur
instruct
briefli
tissu
section
deparaffin
pretreat
heat
proteas
hybrid
targetspecif
probe
niv
hev
ubiquitin
c
bacteri
gene
dapb
use
posit
neg
control
respect
wholetissu
section
select
case
stain
niv
hev
viral
rna
ubc
dapb
rnascop
vs
ffpe
assay
rnascopev
newark
usa
use
ventana
discoveri
xt
slide
autostain
system
ventana
medic
system
inc
tucson
usa
boardcertifi
veterinari
anatom
pathologist
evalu
tissu
slide
statist
analysi
perform
logrank
mantelcox
test
compar
surviv
curv
welchcorrect
onetail
unpair
student
ttest
compar
infecti
viru
titer
tissu
sem
calcul
sampl
pvalu
signific
determin
efficaci
niv
b
vaccin
vaccin
group
hamster
either
singl
dose
primeboost
regim
control
group
either
inject
hamster
gfp
salin
fig
viru
neutral
antibodi
could
detect
singl
dose
niv
b
increas
upon
secondari
dose
averag
vn
titer
sem
singl
dose
boost
contrast
neutral
antibodi
could
detect
serum
obtain
control
group
fig
hamster
challeng
lethal
dose
niv
bangladesh
ld
via
intraperiton
inocul
fig
vaccin
anim
surviv
challeng
show
sign
diseas
weight
loss
stage
throughout
experi
contrast
control
group
anim
succumb
diseas
exhibit
weight
loss
fig
well
respiratori
andor
neurolog
sign
includ
labor
breath
paralyz
hind
leg
statist
analysi
demonstr
surviv
vaccin
group
signific
compar
control
group
p
oropharyng
swab
taken
daili
assess
infecti
viru
limit
dilut
titrat
none
vaccin
anim
shed
viru
timepoint
contrast
control
anim
group
found
shed
viru
fig
four
anim
group
euthan
lung
brain
tissu
harvest
infecti
viru
could
detect
lung
tissu
anim
control
group
averag
titer
sem
x
x
tcid
g
tissu
detect
tissu
vaccin
anim
fig
observ
differ
two
control
group
lung
brain
tissu
harvest
evalu
patholog
chang
none
vaccin
anim
display
pulmonari
patholog
viral
rna
detect
lung
tissu
ish
control
anim
develop
pulmonari
lesion
indistinguish
two
group
hamster
develop
bronchointerstiti
pneumonia
character
multifoc
inflammatori
nodul
center
termin
bronchiol
extend
adjac
alveoli
nodul
compos
larg
number
foami
macrophag
fewer
neutrophil
lymphocyt
admix
small
amount
necrot
debri
case
hemorrhag
fibrin
edema
admix
inflammatori
cell
observ
edema
fibrin
often
extend
surround
alveoli
alveoli
adjac
area
inflamm
thicken
fibrin
edema
small
number
macrophag
neutrophil
previous
observ
niv
infect
hamster
abund
viral
rna
demonstr
ish
area
inflamm
brown
stain
viral
rna
predominantli
found
type
pneumocyt
also
multifoc
present
vascular
bronchiolar
smooth
muscl
endotheli
cell
fig
determin
efficaci
niv
b
niv
malaysia
hev
group
hamster
vaccin
singl
dose
niv
b
singl
dose
gfp
fig
viru
neutral
antibodi
could
detect
vaccin
niv
b
upon
inject
gfp
averag
vn
titer
sem
fig
subsequ
hamster
challeng
either
niv
malaysia
hev
ld
via
intraperiton
inocul
fig
vaccin
anim
challeng
niv
malaysia
surviv
sign
diseas
weight
loss
stage
throughout
experi
contrast
anim
challeng
niv
malaysia
receiv
fgp
succumb
infect
anim
experienc
weight
loss
respiratori
neurolog
sign
fig
statist
analysi
demonstr
surviv
vaccin
group
significantli
differ
control
group
p
oropharyng
swab
taken
daili
assess
infecti
viru
none
vaccin
anim
challeng
niv
malaysia
shed
viru
timepoint
contrast
control
anim
challeng
niv
malaysia
found
shed
viru
fig
four
anim
group
euthan
lung
brain
tissu
harvest
infecti
viru
could
detect
lung
brain
tissu
anim
control
group
averag
viru
titer
lung
sem
x
x
tcid
g
brain
sem
x
x
tcid
g
detect
tissu
vaccin
anim
fig
four
six
vaccin
anim
challeng
hev
succumb
diseas
two
survivor
show
minim
weight
loss
sign
diseas
anim
receiv
fgp
succumb
hev
infect
anim
show
weight
loss
well
respiratori
neurolog
sign
fig
logrank
mantelcox
test
demonstr
surviv
vaccin
group
signific
p
compar
control
group
oropharyng
swab
taken
daili
assess
infecti
viru
none
vaccin
anim
challeng
hev
shed
viru
timepoint
contrast
control
anim
challeng
hev
found
shed
viru
fig
four
anim
group
euthan
lung
brain
tissu
harvest
infecti
viru
detect
three
four
lung
vaccin
anim
lung
control
anim
averag
viru
titer
sem
x
x
x
x
tcid
g
tissu
vaccin
control
anim
respect
statist
differ
infecti
viru
titer
found
two
group
use
unpair
onetail
student
ttest
p
infecti
viru
detect
brain
tissu
anim
control
group
averag
titer
sem
x
x
tcid
g
vaccin
anim
fig
harvest
lung
tissu
evalu
patholog
chang
four
group
hamster
develop
pulmonari
lesion
anim
challeng
hev
control
anim
challeng
niv
malaysia
develop
bronchointerstiti
pneumonia
indistinguish
lesion
describ
control
anim
homolog
challeng
studi
vaccin
hamster
challeng
niv
malaysia
develop
mild
moder
bronchointerstiti
pneumonia
display
evid
pulmonari
edema
fibrin
hemorrhag
ish
demonstr
viral
rna
predominantli
type
pneumocyt
rare
vascular
bronchiolar
smooth
muscl
endotheli
cell
anim
challeng
hev
control
anim
challeng
niv
malaysia
vaccin
anim
challeng
niv
malaysia
howev
littl
rna
present
type
pneumocyt
area
inflamm
fig
final
want
assess
protect
effect
antibodi
elicit
niv
b
vaccin
two
group
hamster
either
vaccin
niv
b
inject
fgp
anim
bled
collect
ml
respect
igg
purifi
ml
pool
serum
ten
anim
per
group
inject
periton
purifi
igg
anim
challeng
lethal
dose
niv
bangladesh
ld
one
day
post
passiv
transfer
fig
unabl
detect
neutral
antibodi
serum
obtain
four
hamster
group
howev
serum
anim
treat
niv
antibodi
posit
elisa
niv
g
protein
albeit
lower
reciproc
titer
antibodi
serum
obtain
singledos
vaccin
anim
fig
one
six
anim
treat
niv
antibodi
succumb
diseas
weight
loss
observ
howev
anim
show
sever
neurolog
sign
none
niv
antibodytr
anim
experienc
weight
loss
sign
diseas
four
six
anim
treat
gfp
antibodi
succumb
diseas
anim
show
weight
loss
respiratori
neurolog
sign
two
surviv
anim
show
sign
diseas
throughout
experi
one
anim
seroconvert
measur
elisa
niv
f
g
protein
suspect
anim
infect
therefor
anim
exclud
surviv
curv
logrank
mantelcox
test
demonstr
surviv
treat
group
signific
p
compar
control
group
fig
oropharyng
swab
taken
daili
assess
infecti
viru
shed
minim
found
one
anim
treat
niv
antibodi
five
anim
treat
gfp
antibodi
fig
four
anim
group
euthan
lung
brain
tissu
harvest
infecti
viru
could
detect
lung
tissu
anim
treat
gfp
antibodi
detect
tissu
anim
treat
niv
antibodi
fig
lung
tissu
harvest
evalu
patholog
chang
group
hamster
develop
pulmonari
lesion
similar
describ
homolog
challeng
studi
howev
niv
antibodytr
hamster
develop
mild
moder
pulmonari
lesion
wherea
control
anim
develop
sever
lesion
addit
none
niv
antibodytr
hamster
display
pulmonari
fibrin
edema
hemorrhag
ish
demonstr
viral
rna
type
pneumocyt
area
inflamm
abund
viral
rna
notabl
less
anim
treat
niv
antibodi
fig
niv
reemerg
infecti
diseas
caus
outbreak
high
casefat
rate
licens
vaccin
niv
current
exist
therefor
key
safe
effect
vaccin
develop
sever
vaccin
candid
explor
differ
anim
model
categor
subunit
vaccin
livevector
vaccin
target
niv
outer
membran
protein
g
andor
f
protect
diseas
lethal
shown
hamster
pig
african
green
monkey
cat
ferret
efficaci
thought
mediat
neutral
antibodi
passiv
transfer
nivb
efficaci
syrian
golden
hamster
antibodi
naiv
anim
also
result
protect
diseas
approach
promis
vaccin
candid
far
move
clinic
trial
studi
present
test
efficaci
vaccin
base
niv
bangladesh
g
protein
replicationdefici
simian
adenoviru
vector
syrian
hamster
primeonli
well
primeboost
regim
protect
syrian
hamster
challeng
lethal
dose
niv
bangladesh
niv
malaysia
partial
protect
hev
challeng
furthermor
antibodi
elicit
vaccin
alon
provid
partial
protect
niv
bangladesh
challeng
two
genet
lineag
niv
describ
niv
malaysia
niv
bangladesh
although
niv
malaysia
caus
outbreak
human
sinc
viru
isol
pteropu
vampyru
pteropu
hypomelanu
pteropu
lylei
malaysia
cambodia
anoth
spillov
event
could
occur
one
vaccin
protect
lineag
niv
viru
would
easiest
cheapest
countermeasur
singledos
vaccin
niv
b
base
niv
bangladesh
fulli
protect
syrian
hamster
lethal
diseas
caus
niv
malaysia
g
protein
niv
strain
use
studi
pairwis
ident
amino
acid
level
amino
acid
differ
scatter
throughout
protein
although
see
steril
protect
niv
malaysia
none
vaccin
anim
show
sign
diseas
protect
lethal
diseas
result
suggest
niv
b
could
protect
lineag
niv
like
niv
hev
speci
henipaviru
genu
thu
investig
crossprotect
niv
b
lethal
challeng
hev
syrian
hamster
g
protein
hev
strain
use
studi
ident
niv
b
g
protein
amino
acid
differ
two
protein
niv
b
protect
partial
hev
challeng
four
six
anim
surviv
challeng
observ
nonsignific
decreas
infecti
hev
titer
lung
brain
tissu
vaccin
anim
compar
control
anim
possibl
diseas
progress
vaccin
anim
delay
compar
control
anim
support
delay
time
death
wherea
averag
time
death
day
control
anim
day
vaccin
anim
crossprotect
niv
hev
vaccin
studi
group
well
adenoassoci
viru
vaccin
express
niv
g
protein
offer
protect
lethal
challeng
hev
hamster
contrast
vaccin
base
hev
provid
full
protect
niv
ferret
nhp
model
likewis
high
level
crossprotect
antibodi
found
sera
hevinfect
individu
wherea
crossprotect
antibodi
limit
nivinfect
individu
might
caus
induct
robust
crossreact
immun
respons
nativ
hev
protein
compar
niv
protein
suggest
bossart
et
al
human
case
hev
associ
direct
contact
infect
hors
intermedi
anim
host
hev
direct
contact
bat
product
yet
associ
hev
infect
human
therefor
like
prevent
hev
hors
complet
prevent
human
case
current
hev
vaccin
equivac
avail
hors
fulli
protect
hev
furthermor
total
number
human
case
contract
hev
rel
low
thu
requir
human
vaccin
hev
therefor
less
urgent
niv
vaccin
previou
work
shown
humor
immun
respons
niv
vaccin
suffici
protect
syrian
hamster
lethal
challeng
niv
likewis
administr
human
neutral
monoclon
antibodi
provid
full
protect
hev
niv
multipl
anim
model
administr
purifi
igg
obtain
niv
b
vaccin
hamster
provid
partial
protect
niv
challeng
furthermor
infecti
viru
could
detect
lung
control
anim
lung
vaccin
anim
thu
previou
studi
niv
belicit
antibodi
abl
provid
protect
lethal
challeng
niv
although
abl
detect
niv
g
proteinspecif
antibodi
serum
obtain
niv
antibodytr
anim
reciproc
titer
much
lower
detect
serum
syrian
hamster
singl
dose
niv
b
possibl
administ
higher
dose
igg
would
led
uniform
protect
two
anim
treat
igg
purifi
anim
receiv
inject
fgp
surviv
lethal
challeng
niv
bangladesh
occasion
surviv
observ
syrian
hamster
model
increas
surviv
rate
might
howev
also
reflect
nonspecif
effect
treatment
igg
report
previous
surviv
rate
significantli
differ
niv
iggtreat
group
control
iggtreat
group
passiv
transfer
experi
show
antibodi
elicit
b
suffici
protect
lethal
challeng
niv
anim
passiv
transfer
experi
observ
day
ensur
two
anim
surviv
would
succumb
diseas
day
syrian
hamster
suitabl
initi
small
anim
model
investig
efficaci
niv
vaccin
follow
african
green
monkey
immun
system
african
green
monkey
like
human
hamster
therefor
seen
relev
anim
model
test
niv
vaccin
base
result
present
current
manuscript
futur
studi
plan
test
niv
b
african
green
monkey
support
coalit
epidem
prepared
innov
cepi
show
niv
b
provid
complet
protect
lethal
diseas
syrian
hamster
challeng
niv
bangladesh
furthermor
niv
b
vaccin
result
complet
surviv
limit
evid
viral
replic
niv
malaysia
challeng
partial
protect
hev
passiv
transfer
antibodi
elicit
niv
b
vaccin
provid
partial
protect
lethal
challeng
niv
bangladesh
